Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237536 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
A Phase 2 study, sponsored by Threshold Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT00237536 is a Phase 2 study that was terminated before completion, run by Threshold Pharmaceuticals. The registered enrollment target is 240 participants.
The verdict
NCT00237536, a Phase 2 study, was terminated before completion, sponsored by Threshold Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
Interventions
- DRUG Lonidamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00237536
The ClinicalTrials.gov registry entry for NCT00237536 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Threshold Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lonidamine is the first listed.
NCT00237536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00237536 about?
NCT00237536 is a clinical study titled "Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia". The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
What is the current status of trial NCT00237536?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2005-06. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00237536?
The interventions under investigation include: Lonidamine (DRUG).
Who is sponsoring clinical trial NCT00237536?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.